Sci Pharmtech (TPE:4119) Short-Term Debt: NT$438 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4119 Sci Pharmtech Inc TPE:4119
78 GF Score
Price NT$56.10
GF Value NT$74.59
Valuation Modestly Undervalued
! 11 Warning Signs
View Full Analysis

What is Sci Pharmtech Short-Term Debt?

Sci Pharmtech TPE:4119 78 Short-Term Debt is NT$438 Mil as of Jun. 2026. GuruFocus rates TPE:4119 with a GF Score™ of 78/100 and a GF Value™ of NT$74.59 (Modestly Undervalued). The stock has 11 warning signs investors should review.

Sci Pharmtech's Short-Term Debt for the quarter that ended in Jun. 2026 was NT$438 Mil.

Sci Pharmtech's quarterly Short-Term Debt increased from Dec. 2025 (NT$679 Mil) to Mar. 2026 (NT$739 Mil) but then declined from Mar. 2026 (NT$739 Mil) to Jun. 2026 (NT$438 Mil).

Sci Pharmtech's annual Short-Term Debt increased from Dec. 2023 (NT$195 Mil) to Dec. 2024 (NT$404 Mil) and increased from Dec. 2024 (NT$404 Mil) to Dec. 2025 (NT$679 Mil).

Sci Pharmtech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Sci Pharmtech Short-Term Debt Related Terms

Sci Pharmtech Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Sci Pharmtech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sci Pharmtech Short-Term Debt Chart

Sci Pharmtech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 112.00 195.00 403.54 678.71

Sci Pharmtech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 436.70 587.95 678.71 738.60 438.40
TPE:4119
78GF Score
Sci Pharmtech Inc TPE:4119
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of NT$438 Mil mean?
Sci Pharmtech (TPE:4119) has a Short-Term Debt of NT$438 Mil as of Jun. 2026.
Is Sci Pharmtech's Short-Term Debt too high?
Sci Pharmtech's current Short-Term Debt is NT$438 Mil. Overall, Sci Pharmtech has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sci Pharmtech's Short-Term Debt compare to ZTS?
Sci Pharmtech's Short-Term Debt of NT$438 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Sci Pharmtech's current Short-Term Debt is NT$438 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sci Pharmtech stock overvalued right now?
Based on GuruFocus' analysis, Sci Pharmtech (TPE:4119) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$74.59, compared to a current price of NT$56.10 — trading 24.8% below its estimated fair value. The current Short-Term Debt is NT$438 Mil. Sci Pharmtech's overall GF Score™ is 78/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Sci Pharmtech (TPE:4119), the current Short-Term Debt is NT$438 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sci Pharmtech (TPE:4119) Overvalued in 2026?

Based on GuruFocus' analysis, Sci Pharmtech stock appears to be undervalued. The current stock price of NT$56.10 is trading 24.8% below its estimated GF Value™ of NT$74.59. GuruFocus considers Sci Pharmtech to be Modestly Undervalued.

Key valuation signals for TPE:4119:

  • Short-Term Debt: NT$438 Mil
  • GF Value™: NT$74.59 vs. price of NT$56.10 (24.8% below fair value)
  • GF Score™: 78/100 with 11 warning signs

No single metric tells the full story. See the TPE:4119 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sci Pharmtech Business Description

Address No.61, Lane 309, Haihu North Road, Luzhu District, Taoyuan, TWN, 33856
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sales of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, Switzerland, Spain, Belgium, Netherlands, and others.
78GF Score

Get the complete analysis for TPE:4119

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$56.10
Price
NT$74.59
GF Value